<DOC>
	<DOCNO>NCT01848054</DOCNO>
	<brief_summary>The purpose study assess efficacy induction treatment buprenorphine/naloxone ( BNX ) sublingual tablet compare induction treatment buprenorphine . The hypothesis start directly OX219 work equally well ( e.g . significantly bad ) start buprenorphine switch OX219 Day 3 .</brief_summary>
	<brief_title>Study Assess Efficacy Safety BNX Sublingual Tablets Induction Treatment Opioid Dependence</brief_title>
	<detailed_description>This prospective , randomize , multicenter , blind , parallel-group , active-controlled , non-inferiority study conduct 13 site within US . Eligible patient participate 8 treatment visit Days 1 , 2 , 3 , 4 , 8 , 15 , 22 , 29 . Effectiveness treatment assess follow : - Retention treatment Day 3 - Clinician patient assessment opioid withdrawal symptom - Assessment opioid craving</detailed_description>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<criteria>Able read , comprehend , sign inform consent form willingly provide write informed consent Prepared engage opioid replacement therapy abstain opioid utilization study drug , illicit drug Male female , 18 65 year age ( inclusive ) Met clinical criterion opioid dependence past 12 month base DSMIVTR Provided buprenorphinenegative urine drug screen prior randomization Provided negative urine pregnancy test Females childbearing potential require use reliable method contraception ( e.g. , hormonal , condom spermicide , intrauterine device [ IUD ] ) screen visit duration study Participants receive opioids pain must receive clearance prescribe physician withdrawn prescribe opioids Generally good health determine investigator Participants demonstrate least mild withdrawal symptom ( defined COWS score &gt; 9 Day 1 predose ) Females pregnant lactating , plan pregnant study Any previous prescribe treatment buprenorphine monotherapy ( e.g. , generic buprenorphine sublingual tablet ) Prescribed treatment buprenorphine naloxone within 90 day prior start treatment Methadone patient daily dose 30 mg past week receive last dose methadone le 30 hour prior start treatment Participants unwilling unable comply requirement protocol Participants participate clinical study medication ( ) deliver used investigational drug device within last 30 day Participants know allergy sensitivity intolerance buprenorphine , naloxone , relate drug Participants staff , affiliate , family member staff personnel directly involve study Participants serious untreated Axis I DSMIVTR psychiatric comorbidity Tongue piercing piercings mouth , include lip cheek Participants current history clinically significant medical disorder condition Participants human immunodeficiency virus ( HIV ) seropositive CD4+ count &lt; 200 active acquire immune deficiency syndrome ( AIDS ) Participants Class III IV congestive heart failure , symptomatic myocardial ischemia , history long QT syndrome . Participants currently take Class 1A antiarrhythmic medication Class III antiarrhythmic medication Participants uncontrolled hypertension clinically significant ECG abnormality Participants pulse oximetry ≤93 % screening , due medical reason . Individuals AST ALT level ≥3 X upper limit normal total bilirubin creatinine ≥1.5 X ULN , screen laboratory assessment Participants know significant liver disease . Participants take medication , nutraceutical , herbal product know CYP3A4 inhibition induction property within 14 day screen . Participants suicidal risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>opioid dependence , buprenorphine/naloxone , sublingual</keyword>
</DOC>